153599-45-2

Basic information

• Product Name: methyl 3-(2-hydroxylethyl)benzoate
• Synonyms: methyl 3-(2-hydroxylethyl)benzoate
• CAS NO: 153599-45-2
• Molecular Weight: 180.203
• Mol File: 153599-45-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: methyl 3-(2-hydroxylethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(2-hydroxylethyl)benzoate(153599-45-2)
• EPA Substance Registry System: methyl 3-(2-hydroxylethyl)benzoate(153599-45-2)

Safety Data

• Hazardous Substances Data: 153599-45-2(Hazardous Substances Data)

Usage

Uses

Methyl 3-(2-Hydroxyethyl)benzoate can be used as SGK kinase inhibitors.

Upstream product

• 75-21-8 oxirane 
• 618-89-3 methyl 3-bromobenzoate 
• 585-76-2 m-bromobenzoic acid 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 38383-50-5 methyl 3-ethenylbenzoate 
• 124038-37-5 methyl 3-(2-oxoethyl)benzoate 
• 61463-60-3 methyl 3-(2-propenyl)benzoate 

Downstream Products

• 1046817-23-5 C₁₇H₁₇NO₄ 
• 52787-19-6 2-(3-(methoxycarbonyl)phenyl) acetic acid 
• 929301-93-9 methyl 3-(2-amino-2-oxoethyl)benzoate 
• 68432-92-8 methyl 3-cyanomethylbenzoate 
• 320730-08-3 3‐(2‐hydroxyethyl)benzoic acid 
• 165801-73-0 3-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester 
• 1026859-90-4 3-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester 
• 165803-79-2 methyl 3-(2-bromoethyl)benzoate 

Relevant articles and documents

Preparation method of m-cyanomethyl methyl benzoate

The invention discloses a preparation method of m-cyanomethyl methyl benzoate. According to the method, m-bromobenzoic acid is used as a starting raw material; the m-bromine methyl methyl benzoate is prepared through esterification; m-methoxy formyl phenethyl alcohol is obtained and prepared through Grignard reaction; through oxidization, the m-methoxy formyl phenylacetic acid is prepared; through amidation and dewatering, the m-cyanomethyl methyl benzoate is finally prepared. The preparation method provided by the invention has the advantages that the design is ingenious; the route is novel; the raw materials have low price and can be easily obtained; the process is simple; the implementation is easy; the yield is high; the purity of the obtained final product is high; the quality is high; no dangerous process exists; the extremely toxic substances of cyanides and expensive cyaniding reagents used in the conventional synthesis are avoided; the requirements on the equipment are simple; the production difficulty and the production cost investment are reduced; the industrial production can be favorably realized; the economic benefits are good.

Pyrrolo pyrimidine ring compound, its use and pharmaceutical composition (by machine translation)

The invention relates to an as TLR7 agonist of the pyrrolo pyrimidine compounds, specifically on a compound of formula (I) compound or its pharmaceutically acceptable salt, preparation method thereof, containing the compounds of the pharmaceutical composition, and its use for the preparation of antiviral drug use. Formula (I) (by machine translation)

8-OXOADENINE COMPOUND

An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1/Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral siseases and cancers, which is represented by the following formula (1): , wherein A is a group of a formula represented by the formula (2): , wherein R2 is a substituted or unsubstituted alkyl group and so on, R3 is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0-2, X1 is oxygen atom, Z is straight or branched chain alkylene, and R1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.